email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1725

LOJ Medical Sciences

Mini Review(ISSN: 2641-1725)

Considerations for Successful Scale-Up To Tox Batches And Phase-Api (Bulk Drugsubstance)

Volume 1 - Issue 3

Krishna Sarma Pathy*

  • Author Information Open or Close
    • Head /QC/QAIPL research centre, Department of Pharmacy, India

    *Corresponding author: Krishnasarma pathy, Head /QC/QAIPL research centre, Department of Pharmacy, India, Email:

Received: August 17, 2018;   Published: August 28, 2018

DOI: 10.32474/LOJMS.2018.01.000112

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Practical Considerations in Pharmaceutical Production Scale-Up- This paper is meant to provide a high-level overview of the steps required to prepare the bulk drug substance API. From first-in-human and through each of the clinical trial stages and into commercialization, scale-up of formulation design is a natural part of pharmaceutical development. At each stage of process development, the batch size increases, from laboratory-scale batches that may be quite small to support preclinical and early clinical stages, to pilot batches that are used in process development, and finally to the production-scale batches needed to support commercialization.

Abstract| Introduction| Conclusion| References|